Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NNMT | P40261 | 2/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6984008 | 0.84 | HCAR3 (0.68) | MAPK1KDM4EL3MBTL1MAPTNNMT | |
| SCHEMBL23832235 | 0.83 | CA12 (0.49) | MAPK1KDM4EMAPTNNMTHCAR3 | |
| SCHEMBL4753377 | 0.83 | NNMT (0.45) | MAPK1KDM4EL3MBTL1NNMTHCAR3 | |
| SCHEMBL30096924 | 0.83 | NNMT (0.45) | MAPK1KDM4EL3MBTL1NNMTHCAR3 | |
| SCHEMBL214930 | 0.83 | LMNA (0.51) | KDM4EMAPTNNMTHCAR3ALDH1A1 | |
| SCHEMBL11005841 | 0.81 | NNMT (0.53) | KDM4EMAPTNNMTHCAR3TDP1 | |
| SCHEMBL1854705 | 0.81 | MAPK1 (0.59) | MAPK1KDM4EL3MBTL1NNMTHCAR3 | |
| SCHEMBL23070480 | 0.80 | NNMT (0.41) | MAPK1KDM4EL3MBTL1NNMTHCAR3 | |
| SCHEMBL15258755 | 0.80 | GAA (0.44) | MAPK1KDM4EL3MBTL1MAPTNNMT | |
| SCHEMBL8722229 | 0.79 | NNMT (0.50) | KDM4EMAPTNNMTHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4121425-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | Akebia Therapeutics Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115551845-A | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022178592-A1 | SOLID PHASE SYNTHESIS OF GLUTAMATE-UREA-LYSINE DERIVED (GUL DERIVED) PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETING CONJUGATES AND THEIR USE AS PRECURSORS FOR THERAPEUTIC AND / OR DIAGNOSTIC AGENTS | Telix International Pty Ltd (AU) | 2022-09-01 | — | — | WO | disclosed |
| CN-114867529-A | Novel heteroaryl triazole compounds as pesticides | 拜耳公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2021188936-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-2678329-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8889704-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140005213-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2678329-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| WO-2012154274-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005213-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | MAPK1 124/4885KDM4E 1413/4885L3MBTL1 805/4885 |
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | MAPK1 215/4885KDM4E 67/4885L3MBTL1 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.